Cargando…

Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey

BACKGROUND: Clinical guidelines agree that preventive treatment should be considered in patients with uncontrolled migraine despite acute medications or patients with ≥4 migraine days per month. However, the criteria to define the effectiveness of treatment and the factors that inform the decision t...

Descripción completa

Detalles Bibliográficos
Autores principales: Pozo‐Rosich, Patricia, Gil‐Gouveia, Raquel, Donnet, Anne, Poole, Anne‐Christine, Gendolla, Astrid, Afridi, Shazia, Sanchez‐De la Rosa, Rainel, Terwindt, Gisela M., Tassorelli, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596543/
https://www.ncbi.nlm.nih.gov/pubmed/34173301
http://dx.doi.org/10.1002/ejp.1831
_version_ 1784600401924849664
author Pozo‐Rosich, Patricia
Gil‐Gouveia, Raquel
Donnet, Anne
Poole, Anne‐Christine
Gendolla, Astrid
Afridi, Shazia
Sanchez‐De la Rosa, Rainel
Terwindt, Gisela M.
Tassorelli, Cristina
author_facet Pozo‐Rosich, Patricia
Gil‐Gouveia, Raquel
Donnet, Anne
Poole, Anne‐Christine
Gendolla, Astrid
Afridi, Shazia
Sanchez‐De la Rosa, Rainel
Terwindt, Gisela M.
Tassorelli, Cristina
author_sort Pozo‐Rosich, Patricia
collection PubMed
description BACKGROUND: Clinical guidelines agree that preventive treatment should be considered in patients with uncontrolled migraine despite acute medications or patients with ≥4 migraine days per month. However, the criteria to define the effectiveness of treatment and the factors that inform the decision to (dis)continue it are not clearly defined in clinical practice. METHODS: Overall, 148 healthcare practitioners from five European countries completed a two‐wave questionnaire. The Steering Committee defined a simulated set of 108 migraine patient profiles based on the combination of five factors (frequency of the attacks, intensity of the attacks, use of acute migraine medications, patient perception and presence/absence of tolerable side effects). These profiles were used in a Delphi survey among European neurologists to identify the criteria that should be used to decide treatment response and continuation using a conjoint analysis approach. RESULTS: Consensus was reached for 82/108 (76%) of profiles regarding treatment response, and for 86/108 (80%) regarding treatment continuation. Multivariable logistic regression analysis showed that a ≥50% reduction in the use of acute migraine medications and positive patient's perception of treatment were the most important factors that lead to the decision of continuing (combined factors, OR = 18.3, 95% CI 13.4–25.05). CONCLUSIONS: This survey identifies two relevant outcome measures: one objective (use of acute migraine treatment medications) and one subjective (positive patient perception) that guide the clinician decision to continue preventive treatment in migraine patients. SIGNIFICANCE: In clinical practice, criteria to define the effectiveness of migraine preventive treatment and factors that guide treatment stop or continuation are not clearly defined. In this simulated clinical setting study, a reduction in the use of acute migraine medications was the factor associated with preventive treatment effectiveness definition. This study also revealed that factors strongly associated with the decision of treatment continuation in real life are the acute migraine medications use and a positive patient's perception of treatment effectiveness.
format Online
Article
Text
id pubmed-8596543
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-85965432021-11-22 Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey Pozo‐Rosich, Patricia Gil‐Gouveia, Raquel Donnet, Anne Poole, Anne‐Christine Gendolla, Astrid Afridi, Shazia Sanchez‐De la Rosa, Rainel Terwindt, Gisela M. Tassorelli, Cristina Eur J Pain Original Articles BACKGROUND: Clinical guidelines agree that preventive treatment should be considered in patients with uncontrolled migraine despite acute medications or patients with ≥4 migraine days per month. However, the criteria to define the effectiveness of treatment and the factors that inform the decision to (dis)continue it are not clearly defined in clinical practice. METHODS: Overall, 148 healthcare practitioners from five European countries completed a two‐wave questionnaire. The Steering Committee defined a simulated set of 108 migraine patient profiles based on the combination of five factors (frequency of the attacks, intensity of the attacks, use of acute migraine medications, patient perception and presence/absence of tolerable side effects). These profiles were used in a Delphi survey among European neurologists to identify the criteria that should be used to decide treatment response and continuation using a conjoint analysis approach. RESULTS: Consensus was reached for 82/108 (76%) of profiles regarding treatment response, and for 86/108 (80%) regarding treatment continuation. Multivariable logistic regression analysis showed that a ≥50% reduction in the use of acute migraine medications and positive patient's perception of treatment were the most important factors that lead to the decision of continuing (combined factors, OR = 18.3, 95% CI 13.4–25.05). CONCLUSIONS: This survey identifies two relevant outcome measures: one objective (use of acute migraine treatment medications) and one subjective (positive patient perception) that guide the clinician decision to continue preventive treatment in migraine patients. SIGNIFICANCE: In clinical practice, criteria to define the effectiveness of migraine preventive treatment and factors that guide treatment stop or continuation are not clearly defined. In this simulated clinical setting study, a reduction in the use of acute migraine medications was the factor associated with preventive treatment effectiveness definition. This study also revealed that factors strongly associated with the decision of treatment continuation in real life are the acute migraine medications use and a positive patient's perception of treatment effectiveness. John Wiley and Sons Inc. 2021-07-13 2021-11 /pmc/articles/PMC8596543/ /pubmed/34173301 http://dx.doi.org/10.1002/ejp.1831 Text en © 2021 The Authors. European Journal of Pain published by John Wiley & Sons Ltd on behalf of European Pain Federation ‐ EFIC ® https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Pozo‐Rosich, Patricia
Gil‐Gouveia, Raquel
Donnet, Anne
Poole, Anne‐Christine
Gendolla, Astrid
Afridi, Shazia
Sanchez‐De la Rosa, Rainel
Terwindt, Gisela M.
Tassorelli, Cristina
Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
title Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
title_full Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
title_fullStr Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
title_full_unstemmed Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
title_short Relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. My‐LIFE European Delphi survey
title_sort relevant factors for neurologists to define effectiveness of migraine preventive drugs and take decisions on treatment. my‐life european delphi survey
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8596543/
https://www.ncbi.nlm.nih.gov/pubmed/34173301
http://dx.doi.org/10.1002/ejp.1831
work_keys_str_mv AT pozorosichpatricia relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT gilgouveiaraquel relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT donnetanne relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT pooleannechristine relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT gendollaastrid relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT afridishazia relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT sanchezdelarosarainel relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT terwindtgiselam relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey
AT tassorellicristina relevantfactorsforneurologiststodefineeffectivenessofmigrainepreventivedrugsandtakedecisionsontreatmentmylifeeuropeandelphisurvey